Showing 4971-4980 of 7296 results for "".
- Aquavit Files Additional IND for New Toxin for Palmar Hyperhidrosishttps://practicaldermatology.com/news/aquavit-files-additional-ind-for-new-toxin-for-palmar-hyperhidrosis/2461625/Aquavit Holdings is asking the US Food and Drug Administration for an additional IND for DTX-024, a treatment of palmar hyperhidrosis using the company’s patented microchannel technology. DTX-024 is a highly purified and clinically tested injectable neuromodulator derived fr
- Burt's Bees Products Improve Redness, Pigmentation, and Reduce Acne-related PIHhttps://practicaldermatology.com/news/burts-bees-products-improve-redness-pigmentation-and-reduce-acne-related-pih/2461624/Burt’s Bees topical bakuchiol-containing sunscreen treats redness and pigmentation of photodamaged facial skin. What’s more, a cream containing Glycyrrhiza glabra (licorice root), Curcuma longa (turmeric root), and Terminalia chebula improves&n
- Take That SKs! DermBiont’s SM-020 Topical Gel Performs Well in Phase 2 Studyhttps://practicaldermatology.com/news/take-that-sks-dermbionts-sm-020-topical-gel-performs-well-in-phase-2-study/2461623/More than 80% of seborrheic keratosis (SK) lesions treated for 14 to 28 days with DermBiont’s SM-020 gel 1.0% had at least a one-point improvement in Physician’s lesion assessment (PLA) score at last visit, according to Phase 2 trial data presented at the
- Takeda’s TYK2 Blocker Impresses in Phase 2b PsO Studyhttps://practicaldermatology.com/news/takedas-tyk2-blocker-impresses-in-phase-2b-pso-study/2461622/Takeda’s TYK2 inhibitor TAK-279 performed well in a Phase 2b study of patients with moderate-to-severe plaque psoriasis. TAK-279 was developed by Nimbus Therapeutics and owned by Takeda. The new findings were presented at the 2023 American Academy of Dermatology (AAD) An
- Timber Pharmaceuticals Announces Publication of Sub-Analysis of Phase 2b CONTROL Studyhttps://practicaldermatology.com/news/timber-pharmaceuticals-announces-publication-of-sub-analysis-of-phase-2b-control-study/2461620/Timber Pharmaceuticals announced the online publication of a sub-analysis of the Phase 2b CONTROL study, which is evaluating TMB-001, a topical isotretinoin formulated using the company’s patented IPEG delivery system, in subjects 9 years of age and older with moderate t
- Galderma's IL-31 Blocker Nemolizumab Wows in PNhttps://practicaldermatology.com/news/galdermas-il-31-blocker-nemolizumab-wows-in-pn/2461619/Galderma’s nemolizumab performed well in Prurigo Nodularis (PN). Nemolizumab is a first-in-class investigational monoclonal antibody directed against the IL-31 receptor alpha that blocks signaling from IL-31.Nemolizumab is an investigational drug and Galderma has not received
- Game On: Level Ex, GladskinMD Introduce Battle of the Biomehttps://practicaldermatology.com/news/game-on-level-ex-gladskinmd-introduce-battle-of-the-biome/2461618/Level Ex is teaming up with Gladskin to create custom, interactive gaming experiences that educate and train medical professionals on the science of endolysin technology and Gladskin’s new product line. As its first collaboration, the companies created a game called Batt
- Eye on OX40 in AD: Rocatinlimab Performs Well in Two Phase 2 Trialshttps://practicaldermatology.com/news/eye-on-ox40-in-ad-rocatinlimab-performs-well-in-two-phase-2-trials/2461617/OX40 is considered a new potential treatment target in atopic dermatitis (AD), and two new studies of the investigational anti-OX40 monoclonal antibody rocatinlimab may add weight to the evidence. Rocatinlimab inhibits and reduces the number of OX40+ pathogenic T cells responsible
- Guselkumab Shows Greater Treatment Persistence than IL-17s in Both Bio-naïve and Bio-experienced Psoriasis Patientshttps://practicaldermatology.com/news/guselkumab-shows-greater-treatment-persistence-than-il-17s-in-both-bio-naive-and-bio-experienced-psoriasis-patients/2461613/Tremyfa (guselkumab) may beat out other biologics when it comes to patient persistence, and a post-hoc analysis of guselkumab showed improvements in scalp psoriasis and quality-of-life measures at week 48. Research found that bio-experienced and bio-naïve psoria
- Bioelectric V.Dox Technology Reduces Biofilm Infection in Burn Woundshttps://practicaldermatology.com/news/bioelectric-vdox-technology-reduces-biofilm-infection-in-burn-wounds/2461611/Vomaris Innovations, Inc. bioelectric V.Dox Technology prevents and reduces biofilm infection in burn wounds, a new study shows. The study appears in Advances in Wound Care. The collaborative research was led by Rodney Chan, M.D, a plastic and reco